Skip to content
value.today

Amgen Inc.: timeline

Every dated event on file, newest first: history, results, dividends, splits, index changes, insider trades, layoffs and recalls, each with its source.

88 events

On the market-cap history; source: Market-cap history on value.today.

$126.3 B$187.8 B$249.2 B202120222023202420252026Nov 3, 2026: Results releasedAug 4, 2026: Results releasedJul 29, 2026: Cybersecurity incidentJun 4, 2026: Recall: Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC Apr 30, 2026: Results releasedFeb 13, 2026: Annual report filed (Form 10-K)Feb 3, 2026: Results releasedDec 31, 2025: Dividend raised 5.9% to $2.52 a shareNov 4, 2025: Results releasedAug 5, 2025: Results releasedMay 1, 2025: Results releasedMar 31, 2025: Dividend raised 5.8% to $2.38 a shareFeb 27, 2025: Recall: Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Only, For Subcutaneous or Intravenous Use OFeb 14, 2025: Annual report filed (Form 10-K)Feb 4, 2025: Results released2025: Record revenue of $36.8 billionOct 30, 2024: Results releasedAug 6, 2024: Results releasedMay 2, 2024: Results releasedMar 31, 2024: Dividend raised 5.6% to $2.25 a shareFeb 14, 2024: Annual report filed (Form 10-K)Feb 6, 2024: Results releasedOct 31, 2023: Results releasedOct 6, 2023: Horizon Therapeutics Public Company became a subsidiaryOct 6, 2023: Acquisition or sale completedAug 3, 2023: Results releasedJun 13, 2023: Closure: 4 employees in San Carlos, CAApr 27, 2023: Results releasedMar 16, 2023: Layoff: 425 employees in Newbury Park, CAJan 30, 2023: Results releasedJan 24, 2023: Layoff: 305 employees in Thousand Oaks, CADec 31, 2022: Dividend raised 9.8% to $2.13 a shareDec 25, 2022: Entered the world's top 100 companies by market capNov 3, 2022: Results releasedAug 4, 2022: Results releasedJun 15, 2022: Closure: 2 employees in CAMay 2, 2022: Recall: MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, MaApr 27, 2022: Results releasedFeb 7, 2022: Results releasedDec 31, 2021: Dividend raised 10.2% to $1.94 a shareNov 2, 2021: Results releasedAug 3, 2021: Results releasedMay 5, 2021: Layoff: 61 employees in CAApr 27, 2021: Results releasedMar 31, 2021: Dividend raised 10.0% to $1.76 a shareFeb 2, 2021: Results releasedJan 28, 2021: Layoff: 531 employees in CAOct 28, 2020: Results releasedAug 31, 2020: Added to the Dow Jones Industrial AverageJul 28, 2020: Results releasedApr 30, 2020: Results releasedMar 31, 2020: Dividend raised 10.3% to $1.6 a shareJan 30, 2020: Results released

Point at a marker under the line to see the event. Green: good news by its nature (a raise, an index entry), orange: bad (a cut, a layoff), grey: neither.

  1. 2026

    1. Nov 3, 2026
      Results released

      Form 8-K filed 03 Nov 2026

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    2. Aug 4, 2026
      Results released

      Form 8-K filed 04 Aug 2026

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    3. Jul 29, 2026
      Cybersecurity incident

      A cybersecurity incident the company judged material.

      Notable 8-K events · source: SEC EDGAR (Form 8-K)

    4. Jun 4, 2026
      Recall: Corlanor (ivabradine) tablets, 7.5mg, 60-count bottles, Rx Only, Amgen Inc., Thousand Oaks, CA 92130 Made In Italy. NDC

      N/A

      Product recalls · source: Drugs (FDA)

    5. Apr 30, 2026
      Results released

      Form 8-K filed 30 Apr 2026

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    6. Feb 13, 2026
      Annual report filed (Form 10-K)

      For the year to 31 Dec 2025

      Annual reports · source: SEC EDGAR (10-K, 20-F, 40-F)

    7. Feb 3, 2026
      Results released

      Form 8-K filed 03 Feb 2026

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

  2. 2025

    1. Dec 31, 2025
      Dividend raised 5.9% to $2.52 a share

      Quarter to 31 Dec 2025

      Dividend raises and cuts · source: SEC filings (dividends declared per share)

    2. Nov 4, 2025
      Results released

      Form 8-K filed 04 Nov 2025

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    3. Aug 5, 2025
      Results released

      Form 8-K filed 05 Aug 2025

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    4. May 1, 2025
      Results released

      Form 8-K filed 01 May 2025

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    5. Mar 31, 2025
      Dividend raised 5.8% to $2.38 a share

      Quarter to 31 Mar 2025

      Dividend raises and cuts · source: SEC filings (dividends declared per share)

    6. Feb 27, 2025
      Recall: Neupogen (filgrastim) For Injection, 300mcg/1 mL, 1 mL Single Dose Vials, Rx Only, For Subcutaneous or Intravenous Use O

      313,620 Vials

      Product recalls · source: Drugs (FDA)

    7. Feb 14, 2025
      Annual report filed (Form 10-K)

      For the year to 31 Dec 2024

      Annual reports · source: SEC EDGAR (10-K, 20-F, 40-F)

    8. Feb 4, 2025
      Results released

      Form 8-K filed 04 Feb 2025

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    9. 2025
      Record revenue of $36.8 billion

      FY2025, the highest of the 19 years on record.

      Company history · source: Financial years

  3. 2024

    1. Oct 30, 2024
      Results released

      Form 8-K filed 30 Oct 2024

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    2. Aug 6, 2024
      Results released

      Form 8-K filed 06 Aug 2024

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    3. May 2, 2024
      Results released

      Form 8-K filed 02 May 2024

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    4. Mar 31, 2024
      Dividend raised 5.6% to $2.25 a share

      Quarter to 31 Mar 2024

      Dividend raises and cuts · source: SEC filings (dividends declared per share)

    5. Feb 14, 2024
      Annual report filed (Form 10-K)

      For the year to 31 Dec 2023

      Annual reports · source: SEC EDGAR (10-K, 20-F, 40-F)

    6. Feb 6, 2024
      Results released

      Form 8-K filed 06 Feb 2024

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

  4. 2023

    1. Oct 31, 2023
      Results released

      Form 8-K filed 31 Oct 2023

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    2. Oct 6, 2023
      Horizon Therapeutics Public Company became a subsidiary

      From the Wikidata entry of Horizon Therapeutics Public Company.

      Company history · source: Wikidata

    3. Oct 6, 2023
      Acquisition or sale completed

      A significant acquisition or disposal of assets was completed.

      Notable 8-K events · source: SEC EDGAR (Form 8-K)

    4. Aug 3, 2023
      Results released

      Form 8-K filed 03 Aug 2023

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    5. Jun 13, 2023
      Closure: 4 employees in San Carlos, CA

      Closure Permanent

      Layoffs · source: State WARN notice

    6. Apr 27, 2023
      Results released

      Form 8-K filed 27 Apr 2023

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    7. Mar 16, 2023
      Layoff: 425 employees in Newbury Park, CA

      Layoff Permanent

      Layoffs · source: State WARN notice

    8. Jan 30, 2023
      Results released

      Form 8-K filed 31 Jan 2023

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    9. Jan 24, 2023
      Layoff: 305 employees in Thousand Oaks, CA

      Layoff Permanent

      Layoffs · source: State WARN notice

  5. 2022

    1. Dec 31, 2022
      Dividend raised 9.8% to $2.13 a share

      Quarter to 31 Dec 2022

      Dividend raises and cuts · source: SEC filings (dividends declared per share)

    2. Dec 25, 2022
      Entered the world's top 100 companies by market cap

      Ranked #80 with $140.8 billion on 25 December 2022, up from #113 on 7 January 2022.

      Company history · source: Market-cap rankings

    3. Nov 3, 2022
      Results released

      Form 8-K filed 03 Nov 2022

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    4. Aug 4, 2022
      Results released

      Form 8-K filed 04 Aug 2022

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    5. Jun 15, 2022
      Closure: 2 employees in CA

      Closure Permanent

      Layoffs · source: State WARN notice

    6. May 2, 2022
      Recall: MVASI (bevacizumab-awwb), Injection, For Intravenous Infusion After Dilution, 100 mg/4 ml, Single dose vial, Rx only, Ma

      15,823

      Product recalls · source: Drugs (FDA)

    7. Apr 27, 2022
      Results released

      Form 8-K filed 27 Apr 2022

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

    8. Feb 7, 2022
      Results released

      Form 8-K filed 07 Feb 2022

      Results releases · source: SEC EDGAR (Form 8-K, item 2.02)

Share price moves are worked out where the site has the listing's daily prices from the exchange itself: India (NSE), Taiwan (TWSE, TPEx), Brazil (B3), Poland (GPW), Russia (MOEX), Hong Kong (HKEX) and Sri Lanka (CSE). US listings have no daily price source on the site yet.